Whether Daubert v. Merrell Dow Pharmaceuticals, Inc. and Federal Rule of Evidence 702 require lower courts to properly analyze the admissibility of evidence involving subjective feature-comparison methods under appropriate scientific principles including multiple, independent, blind-box studies

QUESTION PRESENTED Whether this Court's decision in Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and Federal Rule of Evidence 702 require lower courts to properly analyze the admissibility of evidence involving subjective featurecomparison methods under appropriate scientific principles including multiple, independent, blind-box studies to ensure that the testimony is the product of reliable principles and methods. i